#GLP1 #Pharma #Strategy #MarketAccess #PharmaGambit To view or add a comment, sign in AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS VESALIUS-CV Subgroup Results Show Repatha Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News To view or add a comment, sign in AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS VESALIUS-CV Subgroup Results Show Repatha Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., [...] To view or add a comment, sign in Imagine telling a pharmacist in 2015: A diabetes drug will soon be used for weight loss, heart protection, kidney disease, fatty liver disease, and even sleep apnea. Most people would have laughed

Key benefits Why people compare it 1 Activates telomerase (hTERT) to maintain and extend telomere length 2 13.3% median lifespan extension in CBA mouse models 3 Normalizes melatonin secretion and circadian cortisol rhythm 4 28% cardiovascular mortality reduction in 6-year clinical follow-up 5 Enhanced antioxidant enzyme expression (SOD, glutathione peroxidase) 6 Improved T-cell immunity markers (CD3+, CD4+, CD4/CD8 ratio) 7 1.6-fold reduction in spontaneous tumor incidence in preclinical models 8 Over 35 years and 15+ clinical trials of published research Deep research About Epithalon (Epitalon) Epithalon (also written Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly and a molecular weight of approximately 390.35 Da
(PubMed) Padayatty SJ, Sun H, Wang Y, et al
Does male pattern baldness start suddenly
Le GSSG peut tre converti en GSH par l'enzyme glutathion rductase
Curr Diab Rep 2012;12:2432